Prostatic neoplasms Trials in Toronto, Canada
Conditions / Prostatic neoplasms / Toronto, Canada
Research into Prostatic neoplasms spans multiple therapeutic approaches and trial phases.
43 total trials for this combination
Showing top 10 of 43 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03767244 | A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00036556 | Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer | COMPLETED | PHASE3 |
| NCT02257736 | An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01946204 | A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04720157 | An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02531516 | An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05288166 | A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT00638690 | Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | COMPLETED | PHASE3 |
| NCT01522443 | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer | TERMINATED | PHASE3 |
| NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | RECRUITING | — |